Nemolizumab Sustains Atopic Dermatitis Control Through 3 Years
Long-term data show nemolizumab maintained skin clearance and itch control in atopic dermatitis patients through 3 years of continuous therapy, reinforcing its durability profile.
Topic
Nemolizumab
Topic
Nemolizumab
Nemluvio Shows Three-Year Durability in Atopic Dermatitis
Galderma presented three-year Nemluvio® data at Fall Clinical 2026 showing deep, lasting lesion and itch responses in atopic derm…
Upadacitinib Beats Nemolizumab on EASI-75 and Itch in Indirect AD Analysis
Placebo-adjusted EASI-75 gains of 40.8–51.8 points for upadacitinib vs 13.4 for nemolizumab at Week 16 in an AbbVie-funded MAIC p…
Nemolizumab Sustains Atopic Dermatitis Response at 3 Years
Three-year extension data show nemolizumab sustains response in adults with moderate-to-severe atopic dermatitis, according to co…
Nemluvio Delivers Sustained Improvement in Moderate-to-Severe Atopic Dermatitis
Galderma reports Nemluvio (nemolizumab) delivered sustained improvements in moderate-to-severe atopic dermatitis, reinforcing the…
Nemolizumab Shows Sustained Atopic Dermatitis Gains at 152 Weeks in ARCADIA
Galderma reports 152-week ARCADIA data showing nemolizumab maintained improvements in lesions, itch, sleep and quality of life in…
Nemolizumab Shows Sustained Atopic Dermatitis Benefit to Three Years
Galderma reports at EADV 2026 that nemolizumab (Nemluvio) delivered sustained improvements in moderate-to-severe atopic dermatiti…
Nemolizumab Sustains Atopic Dermatitis Improvements Through Three Years
Galderma's EADV 2026 data show Nemluvio (nemolizumab) sustained improvements in moderate-to-severe atopic dermatitis for up to th…
Nemolizumab Shows Sustained Response up to Three Years in Atopic Dermatitis
Long-term data report sustained nemolizumab response in moderate-to-severe atopic dermatitis patients treated for up to three yea…